SI-BONE, Inc. (NASDAQ:SIBN) Short Interest Update

SI-BONE, Inc. (NASDAQ:SIBN - Get Free Report) was the target of a large decrease in short interest in November. As of November 15th, there was short interest totalling 1,270,000 shares, a decrease of 21.6% from the October 31st total of 1,620,000 shares. Based on an average daily trading volume, of 365,000 shares, the short-interest ratio is currently 3.5 days.

Insider Activity at SI-BONE

In other SI-BONE news, CEO Laura Francis sold 10,048 shares of the firm's stock in a transaction on Monday, November 18th. The shares were sold at an average price of $12.58, for a total transaction of $126,403.84. Following the transaction, the chief executive officer now directly owns 482,875 shares of the company's stock, valued at approximately $6,074,567.50. This trade represents a 2.04 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Anthony J. Recupero sold 3,305 shares of the firm's stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $13.58, for a total value of $44,881.90. Following the transaction, the insider now directly owns 233,412 shares in the company, valued at approximately $3,169,734.96. This represents a 1.40 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 23,093 shares of company stock valued at $299,558 in the last ninety days. Insiders own 3.90% of the company's stock.

Institutional Trading of SI-BONE

A number of large investors have recently made changes to their positions in SIBN. Harbor Capital Advisors Inc. boosted its stake in shares of SI-BONE by 440.5% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 192,380 shares of the company's stock worth $2,487,000 after purchasing an additional 156,790 shares during the last quarter. Vanguard Group Inc. grew its stake in SI-BONE by 1.8% in the 1st quarter. Vanguard Group Inc. now owns 2,463,501 shares of the company's stock worth $40,328,000 after acquiring an additional 43,670 shares during the period. Impax Asset Management Group plc raised its holdings in SI-BONE by 41.3% in the 3rd quarter. Impax Asset Management Group plc now owns 758,521 shares of the company's stock valued at $10,604,000 after acquiring an additional 221,604 shares during the last quarter. Champlain Investment Partners LLC lifted its stake in shares of SI-BONE by 14.7% during the 3rd quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company's stock worth $39,145,000 after purchasing an additional 358,821 shares during the period. Finally, Millrace Asset Group Inc. acquired a new stake in shares of SI-BONE during the third quarter worth $1,056,000. Institutional investors and hedge funds own 98.11% of the company's stock.

SI-BONE Price Performance

SIBN stock traded up $0.29 on Friday, reaching $13.56. The company had a trading volume of 147,807 shares, compared to its average volume of 388,661. The company's fifty day moving average is $13.51 and its 200 day moving average is $14.15. The company has a market cap of $568.71 million, a P/E ratio of -14.42 and a beta of 1.22. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. SI-BONE has a 1 year low of $11.70 and a 1 year high of $21.70.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on SIBN shares. Truist Financial boosted their target price on SI-BONE from $16.00 to $18.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. Needham & Company LLC reiterated a "buy" rating and set a $19.00 price target on shares of SI-BONE in a research note on Wednesday, November 20th. Finally, Morgan Stanley lowered their price objective on SI-BONE from $21.00 to $19.00 and set an "overweight" rating on the stock in a report on Tuesday, August 6th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $23.00.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.